"Precision medicine and personalized health care have always been at the heart of our DNA at Genentech. My goal is to integrate precision medicine efforts into a comprehensive clinical pharmacology strategy to improve patient care."
Since joining Genentech in the Fall of 2007, my primary responsibilities include development of an integrated clinical pharmacology strategy to support oncology drug development and global registration. I was an original member of the International Transport Consortia (ITC), which includes many scientists from academia, FDA and industry. Collectively, the ITC published Membrane Transporters in Drug Development in Nature Reviews Drug Discovery in 2010 to aid drug development in this rapidly evolving field and I have been investigating the impact of pH-dependent solubility on the absorption and pharmacokinetics of anti-cancer drugs. Most recently, our group is working to establish precision medicine efforts within clinical pharmacology to better understand pharmacokinetic variability and adverse drug reactions of investigational drugs and standard-of care drug therapy. Throughout my industrial career, I have had the opportunity to coach and mentor undergraduate, graduate and post-graduate scientists. I also actively contribute to the American Society of Clinical Pharmacology and Therapeutics (ASCPT) organization.
Clin Pharmacol Ther. 2012 Aug; 92(2): 203-13.
Clinical Pharmacology is typically defined as the study of drugs in humans to understand fundamental properties of a drug in the clinic to include: concentration-response, pharmacokinetics (ADME), drug-drug interaction potential, and inter/intra subject variability in response (efficacy and safety). During my early career as a pharmacist, my most fulfilling moments were those opportunities that I had been afforded to act as part of the health care team (MD, RN, pharmacist, patient) to better understand response to medication. This same type of cross-functional teamwork is needed to be successful in drug discovery and development (Bench to bedside/bedside back to the bench). I have had the opportunity to work in both drug discovery and drug development at several organizations that have significantly influenced my commitment to bring life-saving medicines to patients with unmet medical needs. During my industrial tenure, I have supported programmatic advancement (from H2L to phase III) in many therapeutic areas (anti-cancer, inflammation, CNS, and anti-infective) and believe that programmatic challenges represent unique opportunities for pharmaceutical scientists to apply emerging technologies and impact drug development decision-making, innovation and timelines.